Skip to Content

Jordan U. Gutterman, MD

Present Title & Affiliation

Primary Appointment

Professor and Section Chief, Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1964 Medical College of Virginia, Richmond, VA, MD, Medicine
1960 University of Virginia, Charlottesville, VA, BA, Liberal Arts with honors

Postgraduate Training

1971 Advanced Senior Fellow, The University of Texas System Cancer Center, Houston, TX
1968-1969 Chief Resident in Medicine, Duke University Medical Center, Durham, NC
1966-1968 Hematology Fellowship, Duke Medical Center, Durham, NC
1965-1966 Junior Assistant Residency (Medicine), Duke Medical Center, Durham, NC
1964-1965 Internship (Medicine), Duke Medical Center, Durham, NC

Board Certifications

1973 American Board of Internal Medicine/Subspecialty
1972 American College of Physicians
1972 American Board of Internal Medicine


Academic Appointments

Professor, University of Arizona, Tucson, AZ, 7/1996-6/2000
Professor, Albert B. Alkek Institute of Biosciences and Technology, Houston, TX, 12/1994-present
Virginia H. Cockrell Distinguished Professor of Immunology, Department of Molecular Therapeutics, Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 1/1987-6/1999
Professor, The University of Texas System Cancer Center, Houston, TX, 7/1978-9/1981
Associate Professor, Department of Developmental Therapeutics, The University of Texas System Cancer Center, Houston, TX, 9/1974-7/1978
Assistant Professor, Department of Developmental Therapeutics, The University of Texas System Cancer Center, Houston, TX, 7/1972-9/1974
Faculty Associate, Department of Developmental Therapeutics, The University of Texas System Cancer Center, Houston, TX, 10/1971-6/1972
Advanced Senior Fellow, Department of Developmental Therapeutics, The University of Texas System Cancer Center, Houston, TX, 7/1971-9/1971

Administrative Appointments/Responsibilities

Professor and Chairman, Department of Clinical Immunology and Biological Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 1/1987-3/1996
Professor and Deputy Head, Department of Clinical Immunology and Biological Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 7/1984-12/1986
Professor and Section Head, Department of Clinical Immunology and Biological Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 9/1981-7/1984

Other Appointments/Responsibilities

Director, Albert Lasker Medical Research Awards Program, N/A, 1991-present
Executive Vice President, Albert and Mary Lasker Foundation, N/A, 1991-1995
Member, Institute of Medicine Committee on FDA Advisory Committees, N/A, 1991-1993
Member, FDA Advisory Committee on Biological Response Modifiers, N/A, 1990-1994
Member, Alliance for Aging Research Scientific Advisory Board, N/A, 1986-1989
Trustee, Albert and Mary Lasker Foundation, N/A, 1983-present
Member, Rosalind Russell Medical Research Center for Arthritis, N/A, 1980-1983
Member, Cancer Research Institute, N/A, 1979-present
Member, Lasker Foundation, N/A, 1978-1989
Co-Chairman, American Cancer Society, N/A, 1978-1984
Member, National Cancer Institute, N/A, 1978-1981
Member, NCI Committee for the French-American Agreement for Therapeutic Cancer Research, N/A, 1977-1980

Endowed Positions

Virginia H. Cockrell Distinguished Professorship of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, 6/1999-8/2008


Consultant, Receptor BioLogix, Palo Alto, CA, 2006-2008
Consultant, Trellis Bioscience, Mountain View, CA, 2002-2007
Consultant, Burrill & Company, San Francisco, 2000-2006
Consultant, Cell Genesys, San Francisco, CA, 1997-2006

Military or Other Governmental Service

Chief Hematology, Brooke Army Hospital, U.S. Army, 1969-1971

Institutional Committee Activities

Member, Technology Review Committee, 2003
Member, CLL Initiative Committee, 2002
Chairman, Pharmacia Committee, 1999-2003

Honors and Awards

2001 List of Highly Cited Researchers, Institute for Scientific Information
1994 Distinguished Medical Alumnus, Duke University Medical Center
1993 Alpha Omega Alpha Visiting Professor, Medical College of Virginia
1992 Milstein Award, International Society for Interferon Research
1990 George Eastman Cartwright Visiting Professor of Medicine, University of Utah
1981 Senior Research Investigator, Clayton Foundation for Research
1975 Mellors Scholar Lecturer, Memorial Sloan Kettering Institute
1974 Development Award, National Institutes of Health Research Center
1972 Junior Faculty Award, American Cancer Society
1964 William Branch Porter Award, Outstanding Student in Medicine
1962 Alpha Omega Alpha
1960 Phi Beta Kappa
1956 Valedictorian, High School Class

Selected Publications

Peer-Reviewed Original Research Articles

1. Zhang C, Li B, Gaikwad AS, Haridas V, Xu Z, Gutterman JU, Duvic M. Avicin D Selectively Induces Apoptosis and Downregulates p-STAT-3, bcl-2, and Survivin in Cutaneous T-Cell Lymphoma Cells. J Invest Dermatol 128(11):2728-35, 5/2008. e-Pub 5/2008. PMID: 18496567.
2. Gutterman JU, Lai HT, Yang P, Haridas V, Gaikwad A, Marcus S. Effects of the tumor inhibitory triterpenoid avicin G on cell integrity, cytokinesis, and protein ubiquitination in fission yeast. Proc Natl Acad Sci U S A 102:12771-6, 9/2005. PMID: 16118282.
3. Gutterman JU, Choubey D. Retardation of cell proliferation after expression of p202 accompanies an increase in p21(WAF1/CIP1). Cell Growth Differ 10:93-100, 2/1999. PMID: 10074903.
4. Gutterman JU. Recreating an environment for clinical discovery. Clin Cancer Res 3:2594-7, 12/1997. PMID: 9815663.
5. Gutterman JU. Clinical investigators: the driving force behind drug discovery. Nat Biotechnol 15:598-9, 7/1997. PMID: 9219248.
6. Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci U S A 91(4):1198-205, 2/1994. PMID: 8108387.
7. Gutterman JU. Biologic therapy of human cancer. Cancer 70(4 Suppl):906-8, 8/1992. PMID: 1638462.
8. Gutterman JU. Clinical and biological activity of the interferons in hematologic malignancies. Prog Clin Biol Res 288:337-48, 1989. PMID: 2470111.
9. Gutterman JU. The role of interferons in the treatment of hematologic malignancies. Semin Hematol 25(3 Suppl 3):3-8, 7/1988. PMID: 2459780.
10. Gutterman JU, Fine S, Quesada J, Horning SJ, Levine JF, Alexanian R, Bernhardt L, Kramer M, Spiegel H, Colburn W, Trown P, Merigan T, Dziewanowski Z. Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann Intern Med 96(5):549-56, 5/1982. PMID: 6176159.
11. Gutterman JU, Blumenschein GR, Alexanian R, Yap HY, Buzdar AU, Cabanillas F, Hortobagyi GN, Hersh EM, Rasmussen SL, Harmon M, Kramer M, Pestka S. Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med 93(3):399-406, 9/1980. PMID: 6159812.
12. Gutterman JU, Richman SP, McBride CM, Burgess MA, Bartold SL, Kennedy A, Gehan EA, Mavligit G, Hersh EM. Immunotherapy for recurrent malignant melanoma: efficacy of BCG in prolonging the postoperative disease-free interval and survival. Recent Results Cancer Res 68:359-62, 1978. PMID: 752870.
13. Gutterman JU. Cancer systemic active immunotherapy today--Prospects for tomorrow. Cancer Immunol Immunother 2:1-9, 1977.
14. Gutterman JU, Cardenas JO, Blumenschein GR, Hortobagyi G, Burgess MA, Livingston RB, Mavligit GM, Freireich EJ, Gottlieb JA, Hersh EM. Chemoimmunotherapy of advanced breast cancer: prolongation of remission and survival with BCG. Br Med J 2(6046):1222-5, 11/1976. PMID: 791447.
15. Gutterman JU, Mavligit GM, Hersh EM. Chemoimmunotherapy of human solid tumors. Med Clin North Am 60(3):441-62, 5/1976. PMID: 1063907.
16. Gutterman JU, Mavligit GM, Reed R, Burgess MA, Gottlieb J, Hersh EM. Bacillus Calmette-Guerin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma. Cancer Treat Rep 60(2):177-82, 2/1976. PMID: 769970.
17. Gutterman JU, Mavligit GM, Burgess MA, Cardenas JO, Blumenschein GR, Gottlieb JA, McBride CM, Hersh EM, McCredie KB, Bodey GP, Rodriguez V, Freireich EJ. Immunotherapy of breast cancer, malignant melanoma, and acute leukemia with BCG: Prolongation of disease free interval and survival. Cancer Immunol Immunother 1:99-107, 1976.
18. Gutterman JU, Mavligit GM, Blumenshein G, Burgess MA, McBride CM, Hersh EM. Immunotherapy of human solid tumors with Bacillus Calmette-Guerin: prolongation of disease-free interval and survival in malignant melanoma, breast, and colorectal cancer. Ann N Y Acad Sci 277(00):135-59, 1976. PMID: 1069546.
19. Gutterman JU, Mavligit G, Reed R, Richman S, McBride CE, Hersh EM. Immunology and immunotherapy of human-malignant melanoma: historic review and perspectives for the future. Semin Oncol 2(2):155-74, 6/1975. PMID: 790574.
20. Gutterman JU, Hersh EM, Rodriguez V, McCredie KB, Mavligit G, Reed R, Burgess MA, Smith T, Gehan E, Bodey GP, Sr, Freireich EJ. Chemoimmunotherapy of adult acute leukaemia. Prolongation of remission in myeloblastic leukaemia with B.C.G. Lancet 2(7894):1405-9, 12/1974. PMID: 4140327.
21. Gutterman JU, Mavligit GM, Reed RC, Hersh EM. Immunochemotherapy of human cancer. Semin Oncol 1(4):409-23, 12/1974. PMID: 4620443.
22. Gutterman JU, Mavligit G, Gottlieb JA, Burgess MA, McBride CE, Einhorn L, Freireich EJ, Hersh EM. Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and bacillus calmette--guerin. N Engl J Med 291(12):592-7, 9/1974. PMID: 4851001.
23. Gutterman JU, Mavligit G, Burgess MA, McCredie KB, Hunter C, Freireich EJ, Hersh EM. Immunodiagnosis of acute leukemia: detection of residual disease. J Natl Cancer Inst 53(2):389-92, 8/1974. PMID: 4526419.
24. Gutterman JU, Mavligit G, McBride C, Frei E, 3rd, Hersh EM. Immunoprophylaxis of malignant melanoma with systemic BCG: study of strain, dose, and schedule. Natl Cancer Inst Monogr 39:205-12, 12/1973. PMID: 4595319.
25. Gutterman J, Mavligit G, McBride C, Frei E, 3rd, Hersh EM. BCG stimulation of immune responsiveness in patients with malignant melanoma. Preliminary report. Cancer 32(2):321-7, 8/1973. PMID: 4722915.
26. Gutterman JU, Mavligit G, McBride C, Frei E, 3rd, Freireich EJ, Hersh EM. Active immunotherapy with B.C.G. for recurrent malignant melanoma. Lancet 1(7814):1208-12, 6/1973. PMID: 4122562.
27. Gutterman JU, Hersh EM, Mavligit GM, Freireich EJ, Rossen RD, Butler WT, McCredie KB, Bodey GP, Sr, Rodriguez V. Cell-mediated and humoral immune response to acute leukemia cells and soluble leukemia antigen--relationship to immunocompetence and prognosis. Natl Cancer Inst Monogr 37:153-65, 6/1973. PMID: 4576706.
28. Gutterman JU, Mavligit G, McCredie KB, Freireich EJ, Hersh EM. Auto-immunization with acute leukemia cells: demonstration of increased lymphocyte responsiveness. Int J Cancer 11(3):521-6, 5/1973. PMID: 4524745.
29. Gutterman JU, Hersh EM, McCredie KB, Bodey GP, Sr, Rodriguez V, Freireich EJ. Lymphocyte blastogenesis to human leukemia cells and their relationship to serum factors, immunocompetence, and prognosis. Cancer Res 32(11):2524-9, 11/1972. PMID: 4507756.
30. Gutterman JU, Mavligit G, McCredie KB, Bodey GP, Sr, Freireich EJ, Hersh EM. Antigen solubilized from human leukemia: lymphocyte stimulation. Science 177(54):1114-5, 9/1972. PMID: 4506296.
31. Gutterman J, Rodriguez V. Combination chemotherapy of advanced lymphoma. Mil Med 137(7):255-60, 7/1972. PMID: 4624309.
32. Gutterman JU, Rodriguez V, McClure JB. Staging of malignant lymphoma by laparotomy and splenectomy: review of the literature. Mil Med 137(7):251-4, 7/1972. PMID: 4624308.
33. Gutterman J, Rodriguez V, McMullan G. Remission induction of acute leukemia developing in Burkitt's lymphoma. Cancer 29(3):626-9, 3/1972. PMID: 5060645.
34. Gutterman J, Huang AT, Hochstein P. Studies on the mode of action of N-isopropyl-alpha-(2-methylhydrazino)-p-toluamide (MIH). Proc Soc Exp Biol Med 130(3):797-802, 3/1969. PMID: 5773670.

Invited Articles

1. Gutterman JU, Hunt N. Three catalytic lives linked by the Lasker Awards. Nat Med 14(10):1033-5, 10/2008. PMID: 18841143.

Letters to the Editor

1. Gutterman JU, Mavligit GM, Reed RC, Hersh EM. Letter: Treatment of malignant melanoma. Lancet 2(7894):1460, 12/1974. PMID: 4140384.

Grant & Contract Support

Title: Chemical biology of a pentacyclic triterpenoid compound: Modification of critical cysteine residues and redox regulation of G protein signaling by avicins
Funding Source: The Welch Foundation
Role: Principal Investigator
Duration: 6/1/2006 - 5/31/2009
Title: Identification of Potential Anti-Cancer Agents and Other Pharmaceuticals from Plants
Funding Source: Foundation for Research
Role: Principal Investigator
Duration: 1/1/1994 - 1/1/2002

Last updated: 7/29/2015